Newer antibiotics.
D000900:Anti-Bacterial Agents; D001424:Bacterial Infections / Q000188:drug therapy; D002228:Carbenicillin / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D002506:Cephalexin / Q000627:therapeutic use; D002507:Cephaloglycin / Q000627:therapeutic use; D002981:Clindamycin / Q000494:pharmacology / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D005839:Gentamicins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007192:Indenes / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000198:Spectinomycin
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D007093:Imidazoles; D007192:Indenes; D010406:Penicillins; D002981:Clindamycin; D000198:Spectinomycin; D008911:Minocycline; D002228:Carbenicillin; D004318:Doxycycline; D002507:Cephaloglycin; D002506:Cephalexin; D012293:Rifampin